Details

Autor(en) / Beteiligte

• Ringhoffer, Mark
• Wiesneth, Markus
• Harsdorf, Stephanie
• Schlenk, Richard F.
• Schmitt, Anita
• Reinhardt, Peter P.
• Moessner, Margit
• Grimminger, Wolfgang
• Mertens, Thomas
• Reske, Sven N.
• Döhner, Hartmut
• Bunjes, Donald

Titel

CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients

Ist Teil von

• British journal of haematology, 2004-08, Vol.126 (4), p.527-535

Ort / Verlag

Oxford, UK: Blackwell Science Ltd

Erscheinungsjahr

2004

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Summary The present study investigated the effects of CD34+ cell selection in 102 patients using the CliniMACS device. Patients were at high risk for the development of graft versus host disease (GvHD) because of age, or the use of a haploidentical, mismatched or unrelated donor (UD). The median age of the patients was 44 years. The CliniMACS procedure yielded 8·0 × 106 CD34+ cells/kg and the number of residual T cells was 1·3 × 104/kg (median). The median follow up was 20·6 months. The probability of graft failure was 7%. The rate of acute GvHD was low (compatible family donors 10%, UDs 17%, and haploidentical donors 26%) with no patient enduring more than grade II disease. The cumulative incidence of chronic GvHD at the median follow up after transplant was 15% for the compatible family donor group, 40% for the UD group and 78% in the group transplanted from a haploidentical donor Treatment failure was mainly because of transplant‐related mortality, especially aspergillus infection, and not due to relapse. The probability of disease‐free survival, stratified for the risk of treatment failure, was 27% for the high risk, 46% for the intermediate risk and 83% for the low risk group.